Prof. Kirby began by reminding the audience that the development of targeted and effective biological therapies has transformed the outcomes for patients with psoriasis. Biosimilars are approved by regulatory authorities on the basis of rigorous clinical trials that demonstrate they are highly similar to the reference product in terms of quality, safety, and efficacy [2]. Minor differences in clinically inactive components must be supported by strong scientific evidence that these differences are not clinically meaningful. In general, they have lower acquisition costs than the reference product, and biosimilars have been shown to introduce price competition into the market, leading to reduced prices for the treatment of all patients [3]. Consequently, health authorities are increasing their use of biosimilars [4]. Each nation will develop policies on automatic substitution, automatic switching, and interchangeability. Reducing healthcare expenditure on biologics and releasing cost savings to support improved access to these important medicines by using biosimilars will play a vital role in ensuring that psoriasis patients can receive optimal treatment for their disease. The cost savings from biosimilars can improve patient access by broadening national reimbursement criteria to reach parity with European and other international guidelines. For both patients and healthcare providers, this may offer the benefit of improved clinical outcomes. At week 16, patients were blindly switched (or not). Patients were either on ABP501/ABP501 (n=152), adalimumab/adalimumab (n=79), or adalimumab/ABP501 (n=77), and were followed for a year. Switching made no difference (mean % PASI change was identical), showing identical efficacy and safety profiles but at significantly reduced costs.
- Kirby B. FS02, SPIN 2019, 25-27 April, Paris, France.
- Santos SB, et al. Drug Discov Today. 2019 Jan;24(1):293-299.
- QuintilesIMS Report 2017. Retrieved from: https://ec.europa.eu [Accessed 25 April 2019].
- Moorkens E, et al. Front Pharmacol. 2016 Jun 29;7:193.
Posted on
Previous Article
« Switching infliximab biosimilars safe in treating chronic plaque psoriasis Next Article
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis »
« Switching infliximab biosimilars safe in treating chronic plaque psoriasis Next Article
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis »
Table of Contents: SPIN 2019
Featured articles
Letter from the Editor
Aetiology: Triggers and Risk Factors
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Atopic dermatitis and psoriasis: on a spectrum?
Advances in Therapy
Advances in target-oriented therapy: psoriatic arthritis
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease
Novel Considerations
Granulomatous rosacea: exploratory histological markers
Live imaging of cutaneous immune responses
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
ABP501 biosimilar for adalimumab: What you need to know
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Small molecules, apremilast, and TYK2
Related Articles

November 29, 2021
ICD 2021 Highlights Podcast

February 2, 2022
Risankizumab superior to ustekinumab in skin histopathology scores
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy